Published in Gene Therapy Weekly, July 21st, 2005
The merger will marry the skills and capabilities of a classic diagnostic company with a leader in the promising area of pharmacogenomics, creating a combined company that will offer an opportunity to enter the molecular-diagnostics market.
Israel M. Stein, MD, president and CEO of Clinical Data, commented, "Genaissance Pharmaceuticals is a strong strategic fit, enabling us to enter the molecular diagnostics...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly